IL-35 is a newly discovered inhibitory cytokine secreted by regulatory T cells (Tregs) and may have therapeutic potential in several inflammatory disorders. Acute graft-versus-host disease (aGVHD) is a major complication of allogeneic hematopoietic stem cell transplantation and caused by donor T cells and inflammatory cytokines. The role of IL-35 in aGVHD is still unknown. Here we demonstrate that IL-35 overexpression suppresses CD4 + effector T-cell activation, leading to a reduction in alloreactive T-cell responses and aGVHD severity. It also leads to the expansion of CD4 + Foxp3 + Tregs in the aGVHD target organs. Furthermore, IL-35 overexpression results in a selective decrease in the frequency of Th1 cells and an increase of IL-10-producing CD4 + T cells in aGVHD target tissues. Serum levels of TNF-α, IFN-γ, IL-6, IL-22 and IL-23 decrease and IL-10 increases in response to IL-35. Most importantly, IL-35 preserves graft-versus-leukemia effect. Finally, aGVHD grade 2-4 patients have decreased serum IL-35 levels comparing with time-matched patients with aGVHD grade 0-1. Our findings indicate that IL-35 has an important role in reducing aGVHD through promoting the expansion of Tregs and repressing Th1 responses, and should be investigated as the therapeutic strategy for aGVHD.
INTRODUCTION
Acute graft-versus-host disease (aGVHD) is a common and frequently lethal complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT), and is induced by donor T cells and inflammatory cytokines that cause damage to host epithelial tissues, predominantly the skin, liver and gastrointestinal tract. [1] [2] [3] On the other hand, alloreactive T cells also contribute to graftversus-leukemia (GVL) effects that may prevent disease relapse. 3 The immune response is regulated by multiple subtypes of regulatory/suppressor cells. [4] [5] [6] Foxp3 + CD4 + regulatory T cells (Tregs) have been shown to be critically involved in tolerance induction to alloantigens. 7 There are two different Treg subsets, namely natural Tregs (tTregs) and induced Tregs (pTregs). 8 Several lines of evidence demonstrated that donor tTregs could reduce graft-versus-host disease (GVHD). 7, [9] [10] [11] [12] GVHD severity depends, in part, on the balance between the donor tTregs and the effector T cells. 1, 13 Treg-based approaches to treat inflammatory conditions such as GVHD have great potential, but also have limitations. The identification of a well-defined population of Tregs that can be readily generated ex vivo and are stable and potently inhibitory in vivo is a critical goal for effective cell-based immunotherapy. The effector cytokines that have important roles in Treg expansion and function could also provide novel therapeutic approaches.
Epstein-Barr virus-induced gene3 (EBI3) can heterodimerize with IL-12p35 subunit to form IL-35.
14 It can be secreted by CD4 + Foxp3 + Tregs or iTr35 Tregs, a regulatory T-cell population induced by IL-35. 15 Treg suppression is potentiated by target T cells in a cell contact, IL-35-and IL-10-dependent manner. 16 Therefore, the autocrine production of IL-35 by Tregs not only induces more Tregs, but also has an important role in the suppressive functions of Tregs. Human CD8 + Tregs can also produce IL-35. 17 Shen et al. 18 recently identified IL-35-producing B cells as key players in the negative regulation of immunity. IL-35 has been shown to have regulatory and therapeutic potential in mouse models of several inflammatory disorders, including inflammatory bowel disease, experimental autoimmune encephalomyelitis and collagen-induced arthritis. [19] [20] [21] However, whether and how IL-35 may modulate aGVHD remains unknown.
In the current study, we demonstrated that IL-35 could reduce the severity of aGVHD with retention of GVL effects after allo-HSCT. Our results also showed that IL-35 could regulate donor T-cell allo-responses through expanding the Treg population and suppressing Th1 responses. Our findings indicated that exogenous IL-35 could ameliorate aGVHD and may have therapeutic potential in modulating disease progression. 1 Induction and assessment of aGVHD   Eight-to-twelve-week-old female BALB/c (H-2   d   ), male C57BL/6 (B6, H-2   b   ) mice were purchased from SLAC Animal Laboratory (Shanghai, China). Animals were kept in specific pathogen-free conditions. All animal protocols were approved by the institutional review committee at Soochow University. BALB/c recipient mice received lethal total body irradiation (TBI) (850 cGy) from a 60 Co source. Irradiation was followed by the infusion of 1 × 10 7 C57BL/6 T-cell-depleted bone marrow cells and spleen cells (5 × 10 6 ). The severity of GVHD was assessed with a clinical GVHD scoring system as first described by Cooke et al. 22 in a blinded fashion.
MATERIALS AND METHODS
Construction of pcDNA3.1-IL-35 and hydrodynamic gene transfer Two complementary oligonucleotides encoding for four repeats of GGGS linker were designed and used to construct single-chain IL-35 gene using overlap PCR techniques. For hydrodynamic gene transfer (HGT), the recipient mice were injected intravenous with 50 μg of the recombinant plasmid in a total of 2 ml saline solution within 5 s using a 23-gauge needle 24 h before transplantation.
Flow cytometry
Lymphocytes were labeled with conjugated mAb in the presence of purified anti-CD16/32 at saturation to block unspecific staining for 30 min at 4 ℃. For intracellular staining, lymphocytes were stimulated for 4 h with phorbol-12-myristate-13-acetate (50 ng/ml) and ionomycin (500 ng/ml), with brefeldin A added for the final 2 h. Tregs were detected by a mouse Treg staining kit (eBioscience, San Diego, CA, USA). In vivo proliferation was assessed with a BD Pharmingen BrdU APC kit (BD Bioscience, San Diego, CA, USA). Cells were analyzed on a FACS Calibur flow cytometer with CellQuest (BD Bioscience).
Serum cytokine analysis
Cytokines were quantified using cytometric bead array kit (BD Bioscience). The serum concentration of IL-35 was assessed on day 1, 3, 6, 11, 13, 16, 19, 21, 24 after allo-HSCT by enzyme-linked immunosorbent assay (Cloud Clone, Houston, TX, USA).
Mixed lymphocyte reaction and cytotoxicity assay
For mixed lymphocyte reaction (MLR), responders and stimulators were cultured at a final concentration of 0.5 × 10 6 /ml, pulsed with tritiated thymidine (1 mCi/well; Shanghai Institute of Physics, Chinese Academy of Sciences, Shanghai, China) 16-18 h prior to harvesting, and counted on a beta plate reader (PerkinElmer Instruments, Meriden, CT, USA). The IL-2 levels of the supernatants from a 3-day MLR were estimated by the proliferation of CTLL-2 determined by MTT assay. Cytotoxic T-cell activity was determined using a CytoTox 96 nonradioactive cytotoxicity assay kit (Promega, Fitchburg, WI, USA) with responding cells after a 72 h MLR.
Immunohistochemistry and histopathology
The paraffin sections of liver were stained with an anti-EBI3 antibody (DNT27; Lifespan Biosciences, Seattle, WA, USA) and an anti-p35 antibody (Bioworld Technology, St Louis, MN, USA) at concentrations of 1:200 at 37°C for 30 min. The image was developed using a polymer detection system for double immunohistological staining (Zhong Shan Gold Bridge Biotechnology, Beijing, China). Representative samples of lung, liver, small intestine and colon were obtained from transplanted recipients and fixed in 4% formalin, paraffin-embedded, sectioned and stained with hematoxylin and eosin. A semiquantitative scoring system was employed to account for histological changes in four organs. [22] [23] [24] 
Bioluminescent imaging
To examine the GVL effect, 5 × 10 6 luciferase-expressing A20 lymphoma cells (A20-luc, H-2 d , kindly provided by Marcel van den Brink (New York, NY, USA)) were given along with T cell-depleted bone marrow and splenocytes in BALB/c recipients on the day of transplantation. 25 For GVL effect assessment by bioluminescence imaging (BLI), mice were given an intraperitoneal injection of 200 μg firefly luciferin and then anesthetized and imaged weekly using Xenogen, IVIS 100 Bioluminescent Imaging System (Caliper Life Sciences, Hopkinton, MA, USA) to determine the level of tumor burden.
Patients and sample preparation
Twenty-seven patients who underwent allo-HSCT between April and December 2012 at the Center for Hematopoietic Stem Cell Transplantation at the First Affiliated Hospital of Soochow University were included in this study. The characteristics of these patients are shown in Supplementary  Table S1 . Informed consent was obtained from all patients, with approval of the institutional review board. Peripheral blood samples were collected as soon as aGVHD was diagnosed and before therapy was begun. Levels of IL-35 in the plasma samples were determined by enzyme-linked immunosorbent assay (Biolegend, San Diego, CA, USA). Figure S1B) .
RESULTS

IL-35 overexpression ameliorates aGVHD
Clinically, multiple organs could be affected by aGVHD, including liver, small intestine, colon and lung. Ten days after transplantation, the above organs of recipient mice were harvested and histological examination showed markedly reduced inflammation in the lung, intestine and colon of IL-35 HGT recipients (Figure 1e and f). Taken together, these results showed that exogenous IL-35 was capable of mitigating the development of aGVHD. (Figure 3b) . Moreover, the percent of Tregs were reduced to similar levels as those of control groups when IL-35 was neutralized with the antibody treatment (Figures 3a and b) .
To assess the effect of IL-35 on CD4 + T cell and Treg proliferation in vivo, we performed a short 4-h BrdU pulse and Figure S4E) . The percent and number of CD8 + IL-17 + T cells exhibited similar changes (Supplementary Figures S5E and F) . The percent of IL-10-producing CD4 + T cells increased in the liver and intestine, whereas the number of IL-10-producing CD4 + T cells was upregulated in all the organs examined (Figures 4c and d and Supplementary Figure S4A) . The serum levels of TNF-α, IFN-γ, IL-6, IL-22 and IL-23 decreased, whereas IL-10 increased significantly with IL-35 HGT (Figure 4e ). These data indicated that IL-35 reduced the Th1 cytokines while increasing IL-10 production in GVHD target organs after allo-HSCT.
IL-35 expression retains GVL effects
To determine whether the reduction of aGVHD lethality by IL-35 would also interfere with GVL activity, A20-luc (H-2 d ) lymphoma cells were injected intravenously on day 0 to generate murine GVL model. The recipients were monitored for survival and tumor growth was observed weekly using in vivo BLI. A strong signal was observed at day 21 in recipient mice receiving T-cell-depleted bone marrow and A20 cells attesting for tumor growth (Figure 5a ). In contrast, when HGT control-recipient mice received both bone marrow and A20 cells and T cells, a low-BLI signal was observed, indicating that tumor growth was controlled by allogeneic T cells. Ultimately, all recipient mice died from severe aGVHD by day 25. A strong GVL effect was mediated by expression of IL-35 as shown by the absence of BLI signal in recipient mice and was comparable with that obtained with HGT control group. Moreover, the majority of IL-35 HGT recipients survived through the 21-day observation period without or with very little BLI signal, and 33.3% (2/6) of the recipients survived for more than 35 days (Po 0.0001, Figure 5b ). Altogether, these data indicated that IL-35 prevented aGVHD although retained GVL activity. Table S1 ). All patients achieved a sustained and stable donor engraftment. Among the 27 allo-HSCT patients, 22 (81.5%) patients developed aGVHD. Among them, six (27.3%) were grade I, six (27.3%) were grade II, eight (36.4%) were grade III and two (9.1%) were grade IV. CD4 + FoxP3 + T cells from patients with aGVHD grade 2-4 were significantly decreased compared with patients with aGVHD grade 0-1 (Po 0.05; Figure 6a ). Moreover, patients with aGVHD grade 2-4 exhibited significantly lower IL-35 levels than patients with aGVHD grade 0-1 (Po 0.001; Figure 6b ). The serum levels of IL-35 were also positively correlated with the perce,nt of Tregs (Figure 6c) . These results demonstrated that the expression of IL-35 decreased in aGVHD patients and it was positively correlated with the percent of CD4 + FoxP3 + Tregs.
DISCUSSION
In this study we examined the effect of IL-35 on the development of aGVHD in a murine model. Overexpression of IL-35 prevented the development of both immunological and clinical manifestations of aGVHD. Most importantly, IL-35 preserved the GVL effect and had no impairment on the recovery of hematopoiesis and immune cells, resulting in significantly improved survival of mice after allo-HSCT and leukemia challenge. To our knowledge, this is the first report on the role of IL-35 in aGVHD after allo-HSCT. Studies on IL-35 have been hampered by the fact that production of purified rIL-35 is challenging, because the expression level is low and the stability of rIL-35 protein is problematic. This scenario prompted us to adopt systemic plasmid DNAencoding IL-35 gene-delivery approaches to circumvent problems associated with the production of the rIL-35 protein and to provide critical proof-of-principle observations. In murine models of allo-HSCT, overexpression of IL-35 was sufficient to attenuate the development of aGVHD, suggesting that the antiinflammatory properties of IL-35 could be a key regulatory factor in aGVHD. Although the production of rIL-35 is still challenging at the moment, with the advances in protein technology, new approaches could be developed, such as generating functional mutants and stable fusion proteins to increase the production and stability of rIL-35, which would facilitate its potential clinical use.
The protective effect of Tregs on aGVHD has been already demonstrated in several models. + conventional donor T cells after allo-HSCT can protect from GVHD. 27 IL-10 is a well-known suppressive cytokine of T-cell proliferation and cytokine production. Previous studies have observed an association between elevated levels of IL-10 and reduced risk of aGVHD.
28 IL-35-expanded CD4 + CD25 + T-cell population has been shown to produce elevated levels of IL-10. 21 In our study, numbers of CD4 + T cells-secreting IL-10 significantly increased in response to IL-35. Serum levels of IL-10 increased simultaneously, suggesting that IL-35 enhanced IL-10 production. This is consistent with the study that IL-35 protects from collageninduced arthritis by promotion of IL-10 production in vivo. 20 Recent reports demonstrated that IL-10 provided exogenously or by CD4 + Foxp3 + Tregs constrains Th17 and Th1+Th17 cell frequencies. 29, 30 Collectively, our results and previous reports support a specific role for IL-10 induced by IL-35 in attenuating aGVHD in vivo. The contribution of Th17 cells in aGVHD is somewhat controversial. Studies with murine models showed conflicting results, with some data suggesting that Th17 is protective and others indicating a pathogenic role in aGVHD. [31] [32] [33] In humans, there are also divergent results with retrospective reports that circulating and/or tissue-localized Th17 cells can be increased or decreased in aGVHD. [34] [35] [36] [37] [38] [39] In our study, we observed that IL-35 reduced IL-17 production by CD4 + T cells in the small intestine and liver. This is consistent with the observation by Niedbala et al. 21 that EBI3-p35-Fc fusion protein suppresses Th17 cells in vitro and in vivo. However, IL-17 production by CD4 + T cells increased in the lung in response to IL-35. The serum level of IL-17 was not changed. Further investigations are needed to elucidate the role of IL-35 on IL-17 production and the mechanism of organ specificities.
Many studies have demonstrated that alloreactive effector T-cells-mediating GVHD are also important for GVL activity, although not completely overlapping. 40 Therefore, inhibition of GVHD without impairing GVL effect has proven to be a difficult task. IL-35 could suppress alloreactive effector cells and alleviate aGVHD. However, this suppression still allows effective GVL effects. This could be partially mediated by donor natural killer cells. Another possible explanation is that the residual alloreactivity was In conclusion, we present here that IL-35 alleviates aGVHD with retaining of GVL effects. IL-35 expression leads to the Treg expansion and suppression of Th1 cytokine production. Considering the challenge of generating a functional stable Treg population ex vivo for cellular therapy, IL-35 may be a promising agent to investigate and implement clinically for the prevention of aGVHD after allo-HSCT.
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